Send to

Choose Destination
Cell Chem Biol. 2017 Dec 21;24(12):1501-1512.e5. doi: 10.1016/j.chembiol.2017.09.004. Epub 2017 Oct 19.

USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms.

Author information

Department of Molecular Biology and Biophysics, UConn Health, Farmington, CT 06030, USA.
Progenra Inc., Malvern, PA 19355, USA.
Keck Foundation Biotechnology Resource Laboratory, Yale University, New Haven, CT 06511, USA.
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06268, USA.
Department of Molecular Biology and Biophysics, UConn Health, Farmington, CT 06030, USA. Electronic address:


USP7 is a deubiquitinating enzyme that plays a pivotal role in multiple oncogenic pathways and therefore is a desirable target for new anti-cancer therapies. However, the lack of structural information about the USP7-inhibitor interactions has been a critical gap in the development of potent inhibitors. USP7 is unique among USPs in that its active site is catalytically incompetent, and is postulated to rearrange into a productive conformation only upon binding to ubiquitin. Surprisingly, we found that ubiquitin alone does not induce an active conformation in solution. Using a combination of nuclear magnetic resonance, mass spectrometry, computational modeling, and cell-based assays, we found that DUB inhibitors P22077 and P50429 covalently modify the catalytic cysteine of USP7 and induce a conformational switch in the enzyme associated with active site rearrangement. This work represents the first experimental insights into USP7 activation and inhibition and provides a structural basis for rational development of potent anti-cancer therapeutics.


DUB inhibition; DUBs; NMR; USP7; covalent inhibitors; cysteine peptidase; mass spectrometry; ubiquitin binding

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center